Inhibition of Platelet Aggregation in Man by Indobufen (K 3920)
- 1 January 1981
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 9 (1) , 12-17
- https://doi.org/10.1177/030006058100900103
Abstract
A complete crossover trial was undertaken in six healthy volunteers to gain information on dose-effect responses to indobufen by assessing the intensity and duration of the effect of 3 single oral doses of the drug on platelet aggregation induced by threshold concentration of ADP and by 3 added doses of collagen. The results of the study confirm that the activity is dose-related and is reversible since 24 hours after administration it has practically disappeared. The effect of the same dose of indobufen differed significantly according to the amount of collagen added to plasma, whereas increasing doses of indobufen provoked a significantly more marked effect when the amount of inducer employed was the same.This publication has 4 references indexed in Scilit:
- Clinical Pharmacology Studies with Indobufen (K 3920): Inhibitor of Platelet AggregationThe Journal of Clinical Pharmacology, 1980
- Indobufen, a new inhibitor of platelet aggregation. Studies in guinea pigsPharmacological Research Communications, 1979
- Indobufen (K 3920), a new inhibitor of platelet aggregation: Effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to manEuropean Journal of Clinical Pharmacology, 1979
- Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in manEuropean Journal of Clinical Pharmacology, 1979